卡维地洛对不稳定型心绞痛患者血浆炎症因子的影响

目的观察卡维地洛对不稳定型心绞痛（UAP）患者高敏C反应蛋白（hs-CRP）、白介素-6（IL-6）及细胞间可溶性黏附分子1（sICAM-1）水平的影响。方法UAP患者62例采用完全随机化方法分成对照组（n=30）和治疗组（n=32）,在常规抗血小板、扩血管治疗基础上,对照组予美托洛尔（12.5mg,2次/d×3d）口服,治疗组服卡维地洛（6.25mg,2次/d×3d）,在治疗前后分别测定hs-CRP、IL-6、sICAM-1值。结果对照组和治疗组在治疗前hs-CRP、IL-6、sICAM-1均无显著性差异;用药后两组3指标均较用药前显著降低（P<0.05）;治疗组在用药后IL-6、sI-CAM-1显著低于对照组（P<0.05）。同时,用药后两组患者的心率、血压、心肌耗氧量均较用药前显著降低（P<0.05）,治疗组的心肌耗氧量显著低于对照组（P<0.05）。结论卡维地洛可显著降低UAP患者的炎症因子IL-6、sICMA-1水平。

Effects of Carvedilol on function of endothelium in patients with unstable angina pectoris

AIM To observe the effect of Carvedilol on the circulating levels of high sensitivity C-reactive protein(hs-CRP), interleukin-6(IL-6)and soluble intercellular adhesion molecule-1(sICAM-1) in patients with unstable angina pectoris (UAP). METHODS Sixty-two patients with UAP were randomly divided into two groups. On the basis of ant iplatelet and vasodilator remedy, the patients in control group (n= 30) were given Metoprolol, while the patients in therapeutic group (n= 32) were given carvedilol. Before and 3 d after the treatment, venous blood samples were taken and the levels of serum hs-CRP, IL-6 and sICAM-1 were measured. RESULTS The levels of circulating hs-CRP, IL-6 and sICAM-1 between control group and carvedilol group were not significantly different before the treatment. After the treatment, the levels of hs-CRP, IL-6 and sICAM-1 in control group and carvedilol group were significantly lower than the base line (P<0.05), whereas the levels of IL-6 and sICAM-1 in carvedilol group were significantly lower than those in control group (P<0.05). The levels rate, blood pressure,myocardial consumption of oxygen in control group and carvediol group were significantly lower than base line(P<0.05). CONCLUSION Carvedilol can decrease the circulating levels of IL-6, sICAM-1 inflammatory factors in patients with UAP.